{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:17:38Z","timestamp":1794359858808,"version":"4.9.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nucl. Med."],"abstract":"<jats:p>Neuroendocrine tumors (NETs) rarely metastasize to the brain. However, when they occur, NET brain metastases are associated with a poor prognosis. Due to their low incidence, NET brain metastases are poorly studied, with few data to guide a consensus for management. Prior reports have documented treatment with chemotherapy, resection, whole brain radiation therapy, and stereotactic radiosurgery, all with low rates of survival. We present a case of a patient with type 3 well-differentiated gastric NET with widespread metastatic disease, including central nervous system lesions in the pineal gland and left cerebellopontine angle (CPA), which were avid on <jats:sup>68<\/jats:sup>Ga-dotatate positron emission tomography. The patient received four doses of 200\u2005mCi (7.4\u2005GBq) lutetium-177 oxodotreotide (<jats:sup>177<\/jats:sup>Lu-dotatate) administered every 8 weeks over the course of 6 months. The treatments provided local control of the pineal and CPA lesions for 23 months until the development of diffuse leptomeningeal progression that necessitated further therapies. <jats:sup>177<\/jats:sup>Lu-dotatate may be a viable treatment for local control of NET brain metastases. More studies are needed to validate its efficacy in this clinical scenario.<\/jats:p>","DOI":"10.3389\/fnume.2023.1074948","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T08:22:02Z","timestamp":1677140522000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: Efficacy of lutetium-177 oxodotreotide for neuroendocrine tumor with central nervous system metastases"],"prefix":"10.3389","volume":"3","author":[{"given":"Nwanneka","family":"Okwundu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heloisa P.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel C.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald M.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1097\/SMJ.0b013e3181b67356","article-title":"Carcinoid tumors of the gastrointestinal tract","volume":"102","author":"Ghevariya","year":"2009","journal-title":"South Med J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1002\/cncr.24498","article-title":"Pulmonary neuroendocrine\/carcinoid tumors: a review article","volume":"115","author":"Bertino","year":"2009","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/j.1464-410X.2007.07360.x","article-title":"Carcinoid tumours of the testis","volume":"101","author":"Stroosma","year":"2008","journal-title":"BJU Int"},{"key":"B4","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/0002-9394(60)92065-1","article-title":"Tumor of orbit. Metastatic from malignant bronchial adenoma","volume":"49","author":"Kulvin","year":"1960","journal-title":"Am J Ophthalmol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/0002-9394(80)90279-2","article-title":"Orbital carcinoid tumor metastatic from the colon","volume":"89","author":"Rush","year":"1980","journal-title":"Am J Ophthalmol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1677\/ERC-09-0108","article-title":"Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin","volume":"17","author":"Basu","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumors of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.5858\/arpa.2019-0665-RA","article-title":"What is new in the 2019 world health organization (WHO) classification of tumors of the digestive system: review of selected updates on neuroendocrine neoplasms, appendiceal tumors and molecular testing","volume":"145","author":"Assarzadegan","year":"2021","journal-title":"Arch Pathol Lab Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1200\/JCO.2010.33.2056","article-title":"Future directions in the treatment of neuroendocrine tumors: consensus report of the national cancer institute neuroendocrine tumor clinical trials planning meeting. Journal of clinical oncology. Vol 29","volume":"29","author":"Kulke","year":"2011","journal-title":"Am Soci Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.clon.2011.08.006","article-title":"The management of neuroendocrine tumours: current and future medical therapy options","volume":"24","author":"Oberg","year":"2012","journal-title":"Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/819193","article-title":"A multimodal approach to the management of neuroendocrine tumour liver metastases","volume":"2012","author":"Basuroy","year":"2012","journal-title":"Int J Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","article-title":"Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin","volume":"81","author":"Mitry","year":"1999","journal-title":"Br J Cancer"},{"key":"B14","volume-title":"LUTATHERA (Lutetium lu 177 dotatate) [package insert]","year":"2018"},{"key":"B15","first-page":"1023","article-title":"177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev","volume-title":"Gastroenterol Hepatol","author":"Das","year":"2019"},{"key":"B16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/nejmoa1607427","article-title":"Phase 3 trial of 177 lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"175201763","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-dotatate Plus long-acting octretide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumors (NETTER-1): final overall survival and long-term safety results from an open label, randomized, controlled phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/ph12030114","article-title":"Lutathera\u00ae: the first FDA-and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals"},{"key":"B19","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/EJE-14-0488","article-title":"GEPNETs update: radionuclide therapy in neuroendocrine tumors","volume":"172","author":"Van der Zwan","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/RLU.0000000000003818","article-title":"Pineal gland metastasis from gastric carcinoid- A rare manifestation","volume":"47","author":"Fine","year":"2022","journal-title":"Clin Nucl Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s12149-015-1000-8","article-title":"68Ga-DOTATATE Uptake in pineal gland, a rare physiological variant: case series","volume":"29","author":"Riaz","year":"2015","journal-title":"Ann Nucl Med"},{"key":"B22","first-page":"403","article-title":"Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability","volume":"36","author":"Haldemann","year":"1995","journal-title":"J Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-001-0717-x","article-title":"Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study","volume":"29","author":"Schumacher","year":"2002","journal-title":"Eur J Nucl Med Imaging."},{"key":"B24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1053\/snuc.2002.31027","article-title":"Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings","volume":"22","author":"De Jong","year":"2002","journal-title":"Semin Nucl Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1053\/j.semnuclmed.2006.01.001","article-title":"Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors","volume":"36","author":"Valkema","year":"2006","journal-title":"Semin Nucl Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2967\/jnumed.109.072819","article-title":"Response of recurrent high-grade glioma to treatment with 90Y-DOTATOC","volume":"51","author":"Heute","year":"2010","journal-title":"J Nucl Med Off Publ Soc Nucl Med."},{"key":"B27","first-page":"1025","article-title":"Locoregional regulatory peptide targeting with the diffusible somatostatin analog 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas","volume":"5","author":"Merlo","year":"1999","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1212\/wnl.36.6.745","article-title":"Neurologic complications of carcinoid","volume":"36","author":"Patchell","year":"1986","journal-title":"Neurology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1002\/cncr.20659","article-title":"Carcinoid metastasis to the brain","volume":"101","author":"Hlatky","year":"2004","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1023\/B:NEON.0000014517.56866.bc","article-title":"Single brain metastases of carcinoid tumors","volume":"66","author":"Maiuri","year":"2004","journal-title":"J Neurooncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e5509","DOI":"10.7759\/cureus.5509","article-title":"Stereotactic radiosurgery for carcinoid brain metastasis: a case report","volume":"11","author":"Cao","year":"2019","journal-title":"Cureus"},{"key":"B32","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1159\/000287277","article-title":"ENETS Consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors","volume":"91","author":"Pavel","year":"2010","journal-title":"In Neuroendocrinology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"314","DOI":"10.4103\/1793-5482.145319","article-title":"Malignant metastatic carcinoid presenting as brain tumor","volume":"11","author":"Sundar","year":"2016","journal-title":"Asian J Neurosurg"},{"key":"B34","doi-asserted-by":"publisher","first-page":"502","DOI":"10.4065\/80.4.502","article-title":"Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors","volume":"80","author":"Delaunoit","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"B35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.brainresrev.2007.06.002","article-title":"The circumventricular organs: an atlas of comparative anatomy and vascularization","volume":"56","author":"Duvernoy","year":"2007","journal-title":"Brain Res Rev"},{"key":"B36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jocn.2015.10.006","article-title":"Choroid plexus of the fourth ventricle: review and anatomic study highlighting anatomical variations","volume":"26","author":"Tubbs","year":"2016","journal-title":"J Clin Neurosci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00281-009-0177-0","article-title":"The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction","volume":"31","author":"Engelhardt","year":"2009","journal-title":"Semin Immunopathol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1023\/a:1008338312647","article-title":"Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: groupe fran\u00e7ais de pneumo-canc\u00e9rologie (GFPC) protocol 95-1","volume":"12","author":"Robinet","year":"2001","journal-title":"Ann Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"JCO2018783118","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS Response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","article-title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial","volume":"31","author":"Montemurro","year":"2020","journal-title":"Ann Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s00259-009-1216-8","article-title":"Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-phe (1)-tyr (3)-octreotate","volume":"37","author":"Sandstrom","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B44","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1080\/0284186X.2017.1286384","article-title":"Combining radioiodine and external beam radiation therapy: the potential of integrated treatment planning for differentiated thyroid cancer","volume":"56","author":"Mikalsen","year":"2017","journal-title":"Acta Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1200\/JCO.2016.69.7144","article-title":"Management of brain metastases in tyrosine kinase inhibitor-na\u00efve epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis","volume":"35","author":"Magnuson","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Nuclear Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2023.1074948\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T08:22:06Z","timestamp":1677140526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2023.1074948\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":45,"alternative-id":["10.3389\/fnume.2023.1074948"],"URL":"https:\/\/doi.org\/10.3389\/fnume.2023.1074948","relation":{},"ISSN":["2673-8880"],"issn-type":[{"value":"2673-8880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"article-number":"1074948"}}